Skip to main content

TNF inhibitor

RT @doctorRBC: Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐ï

Robert B Chao, MD doctorRBC

1 year ago
Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX
RT @swethaann23: ⭐️Prevalent drug utilization was not related to enthesitis activity
⭐️Prevalent use of cDMARDs

swethaann23 swethaann23

1 year ago
⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annu

Dr. John Cush RheumNow

1 year ago
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
RT @drdavidliew: Put those two RF together (essentially nailing down RA pts at risk of cancer):

age >65 or ever smok

David Liew drdavidliew

1 year ago
Put those two RF together (essentially nailing down RA pts at risk of cancer): age >65 or ever smoked, all tofa vs TNFi: HR 1.55 (1.05-2.30) age >65 or ever smoked, tofa 5 bid vs TNFi: HR 1.44 (0.93-2.24) neither RF, all tofa vs TNFi: HR 1.16 (0.53-2.55) #ACR21 @RheumNow https://t.co/Uvr4wBhFVF
switch.jpg
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…
RT @RichardPAConway: Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disea

Richard Conway RichardPAConway

1 year ago
Therapeutic drug monitoring ⬆️ infliximab efficacy in RCT. 17.6% improvement in sustained disease control. Consistent across all rheumatic and non-rheumatic diseases. Abstr#1946 #ACR21 @RheumNow https://t.co/D1Ppb58fB8
RT @RichardPAConway: ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared

Richard Conway RichardPAConway

1 year ago
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
RT @drdavidliew: ORAL Surveillance: MACE and malignancy are getting all the attention...

but did you know that non-zost

David Liew drdavidliew

1 year ago
ORAL Surveillance: MACE and malignancy are getting all the attention... but did you know that non-zoster infections are also more likely with tofacitinib vs TNFis? #ACR21 ABST1684 @RheumNow https://t.co/GiBkvPYs4j
×